Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis

NCT07299019 is registered in ClinicalTrials.gov with Zenas BioPharma (USA), LLC as lead sponsor.

NCT NCT07299019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07299019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis
Lead sponsor
Zenas BioPharma (USA), LLC
Phase
Phase 3
Overall status
Recruiting
Start date
March 23, 2026
Completion date
July 31, 2030
Enrollment
990 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

secondary progressive multiple sclerosis